TRIM16 and prostate carcinoma: It has been confirmed that TRIM16 overexpression inhibits epithelial-to-mesenchymal transition (EMT) process and the invasion of tumor cells in prostate carcinoma and also in non-small cell lung cancer (NSCLC) cells (Huo et al., 2015; Qi et al., 2016).